Literature DB >> 12470802

Abeta as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease.

Stephen R Robinson1, Glenda M Bishop.   

Abstract

Research into Alzheimer's disease (AD) has been guided by the view that deposits of fibrillar amyloid-beta peptide (Abeta) are neurotoxic and are largely responsible for the neurodegeneration that accompanies the disease. This 'amyloid hypothesis' has claimed support from a wide range of molecular, genetic and animal studies. We critically review these observations and highlight inconsistencies between the predictions of the amyloid hypothesis and the published data. We show that the data provide equal support for a 'bioflocculant hypothesis', which posits that Abeta is normally produced to bind neurotoxic solutes (such as metal ions), while the precipitation of Abeta into plaques may be an efficient means of presenting these toxins to phagocytes. We conclude that if the deposition of Abeta represents a physiological response to injury then therapeutic treatments aimed at reducing the availability of Abeta may hasten the disease process and associated cognitive decline in AD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12470802     DOI: 10.1016/s0197-4580(01)00342-6

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  40 in total

Review 1.  Amyloid-β peptide: Dr. Jekyll or Mr. Hyde?

Authors:  Daniela Puzzo; Ottavio Arancio
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 2.  The effects of cholesterol on learning and memory.

Authors:  Bernard G Schreurs
Journal:  Neurosci Biobehav Rev       Date:  2010-05-12       Impact factor: 8.989

Review 3.  Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim.

Authors:  Orly Weinreb; Silvia Mandel; Orit Bar-Am; Tamar Amit
Journal:  J Neural Transm (Vienna)       Date:  2011-03-01       Impact factor: 3.575

4.  The GRK2 Overexpression Is a Primary Hallmark of Mitochondrial Lesions during Early Alzheimer Disease.

Authors:  Mark E Obrenovich; Hector H Palacios; Eldar Gasimov; Jerzy Leszek; Gjumrakch Aliev
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-03-03

Review 5.  Mechanisms of AD neurodegeneration may be independent of Aβ and its derivatives.

Authors:  Nikolaos K Robakis
Journal:  Neurobiol Aging       Date:  2010-07-01       Impact factor: 4.673

6.  Haptoglobin modulates beta-amyloid uptake by U-87 MG astrocyte cell line.

Authors:  Bernardetta Maresca; Maria Stefania Spagnuolo; Luisa Cigliano
Journal:  J Mol Neurosci       Date:  2014-11-18       Impact factor: 3.444

7.  The biochemical aftermath of anti-amyloid immunotherapy.

Authors:  Chera L Maarouf; Ian D Daugs; Tyler A Kokjohn; Walter M Kalback; R Lyle Patton; Dean C Luehrs; Eliezer Masliah; James Ar Nicoll; Marwan N Sabbagh; Thomas G Beach; Eduardo M Castaño; Alex E Roher
Journal:  Mol Neurodegener       Date:  2010-10-07       Impact factor: 14.195

8.  Cholesterol, copper, and accumulation of thioflavine S-reactive Alzheimer's-like amyloid beta in rabbit brain.

Authors:  D Larry Sparks
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 9.  Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.

Authors:  Abraham Fisher
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

Review 10.  Insights into cerebrovascular complications and Alzheimer disease through the selective loss of GRK2 regulation.

Authors:  Mark E Obrenovich; Ludis A Morales; Celia J Cobb; Justin C Shenk; Gina M Méndez; Kathryn Fischbach; Mark A Smith; Eldar K Qasimov; George Perry; Gjumrakch Aliev
Journal:  J Cell Mol Med       Date:  2008-10-06       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.